vs
COMPX INTERNATIONAL INC（CIX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
COMPX INTERNATIONAL INC的季度营收约是REGENXBIO Inc.的1.2倍（$37.7M vs $30.3M），COMPX INTERNATIONAL INC净利率更高（12.4% vs -221.3%，领先233.7%），REGENXBIO Inc.同比增速更快（43.0% vs -1.9%），COMPX INTERNATIONAL INC自由现金流更多（$11.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.4%）
COMPX国际是一家多元化安全与控制产品制造商，主营高性能锁具系统、电子门禁解决方案、人体工学工作站部件及船用五金，核心市场覆盖北美、欧洲，服务商业、住宅、工业、医疗、休闲船舶等领域客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CIX vs RGNX — 直观对比
营收规模更大
CIX
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出44.9%
-1.9%
净利率更高
CIX
高出233.7%
-221.3%
自由现金流更多
CIX
多$64.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.7M | $30.3M |
| 净利润 | $4.7M | $-67.1M |
| 毛利率 | 32.1% | — |
| 营业利润率 | 15.0% | -190.0% |
| 净利率 | 12.4% | -221.3% |
| 营收同比 | -1.9% | 43.0% |
| 净利润同比 | 3.6% | -31.2% |
| 每股收益（稀释后） | $0.38 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIXRGNX
| Q4 25 | $37.7M | $30.3M | ||
| Q3 25 | $40.0M | $29.7M | ||
| Q2 25 | $40.4M | $21.4M | ||
| Q1 25 | $40.3M | $89.0M | ||
| Q4 24 | $38.4M | $21.2M | ||
| Q3 24 | $33.7M | $24.2M | ||
| Q2 24 | $35.9M | $22.3M | ||
| Q1 24 | $38.0M | $15.6M |
净利润CIXRGNX
| Q4 25 | $4.7M | $-67.1M | ||
| Q3 25 | $4.2M | $-61.9M | ||
| Q2 25 | $5.5M | $-70.9M | ||
| Q1 25 | $5.1M | $6.1M | ||
| Q4 24 | $4.5M | $-51.2M | ||
| Q3 24 | $3.5M | $-59.6M | ||
| Q2 24 | $4.8M | $-53.0M | ||
| Q1 24 | $3.8M | $-63.3M |
毛利率CIXRGNX
| Q4 25 | 32.1% | — | ||
| Q3 25 | 27.6% | — | ||
| Q2 25 | 31.9% | — | ||
| Q1 25 | 30.2% | — | ||
| Q4 24 | 28.8% | 70.2% | ||
| Q3 24 | 28.1% | 48.8% | ||
| Q2 24 | 31.1% | 52.5% | ||
| Q1 24 | 25.5% | 72.6% |
营业利润率CIXRGNX
| Q4 25 | 15.0% | -190.0% | ||
| Q3 25 | 11.9% | -176.3% | ||
| Q2 25 | 15.7% | -296.3% | ||
| Q1 25 | 14.6% | 13.6% | ||
| Q4 24 | 12.7% | -242.1% | ||
| Q3 24 | 9.9% | -256.6% | ||
| Q2 24 | 14.2% | -251.3% | ||
| Q1 24 | 9.8% | -408.8% |
净利率CIXRGNX
| Q4 25 | 12.4% | -221.3% | ||
| Q3 25 | 10.6% | -208.3% | ||
| Q2 25 | 13.5% | -331.8% | ||
| Q1 25 | 12.7% | 6.8% | ||
| Q4 24 | 11.7% | -241.3% | ||
| Q3 24 | 10.3% | -246.3% | ||
| Q2 24 | 13.5% | -237.7% | ||
| Q1 24 | 9.9% | -405.4% |
每股收益（稀释后）CIXRGNX
| Q4 25 | $0.38 | $-1.30 | ||
| Q3 25 | $0.34 | $-1.20 | ||
| Q2 25 | $0.44 | $-1.38 | ||
| Q1 25 | $0.42 | $0.12 | ||
| Q4 24 | $0.37 | $-0.99 | ||
| Q3 24 | $0.28 | $-1.17 | ||
| Q2 24 | $0.39 | $-1.05 | ||
| Q1 24 | $0.31 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $54.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $138.6M | $102.7M |
| 总资产 | $156.2M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CIXRGNX
| Q4 25 | $54.1M | $230.1M | ||
| Q3 25 | $46.3M | $274.2M | ||
| Q2 25 | $56.2M | $323.3M | ||
| Q1 25 | $56.1M | $267.9M | ||
| Q4 24 | $60.8M | $234.7M | ||
| Q3 24 | $58.8M | $255.5M | ||
| Q2 24 | $82.1M | $290.4M | ||
| Q1 24 | $75.6M | $338.7M |
股东权益CIXRGNX
| Q4 25 | $138.6M | $102.7M | ||
| Q3 25 | $137.7M | $161.5M | ||
| Q2 25 | $149.5M | $213.7M | ||
| Q1 25 | $147.6M | $274.2M | ||
| Q4 24 | $146.1M | $259.7M | ||
| Q3 24 | $145.3M | $301.4M | ||
| Q2 24 | $170.2M | $348.3M | ||
| Q1 24 | $168.9M | $390.7M |
总资产CIXRGNX
| Q4 25 | $156.2M | $453.0M | ||
| Q3 25 | $153.7M | $525.2M | ||
| Q2 25 | $164.8M | $581.0M | ||
| Q1 25 | $162.2M | $490.9M | ||
| Q4 24 | $163.0M | $466.0M | ||
| Q3 24 | $160.1M | $519.1M | ||
| Q2 24 | $185.1M | $569.4M | ||
| Q1 24 | $181.7M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $11.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 30.3% | -174.0% |
| 资本支出强度资本支出/营收 | 1.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.57× | — |
| 过去12个月自由现金流最近4个季度 | $19.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CIXRGNX
| Q4 25 | $12.0M | $-52.3M | ||
| Q3 25 | $6.3M | $-56.0M | ||
| Q2 25 | $4.7M | $-49.3M | ||
| Q1 25 | $-137.0K | $33.6M | ||
| Q4 24 | $7.3M | $-31.6M | ||
| Q3 24 | $4.1M | $-40.5M | ||
| Q2 24 | $9.8M | $-45.5M | ||
| Q1 24 | $1.7M | $-55.5M |
自由现金流CIXRGNX
| Q4 25 | $11.4M | $-52.8M | ||
| Q3 25 | $5.3M | $-56.5M | ||
| Q2 25 | $3.4M | $-49.7M | ||
| Q1 25 | $-959.0K | $32.6M | ||
| Q4 24 | $7.1M | $-32.7M | ||
| Q3 24 | $3.6M | $-40.9M | ||
| Q2 24 | $9.4M | $-46.0M | ||
| Q1 24 | $1.4M | $-56.0M |
自由现金流率CIXRGNX
| Q4 25 | 30.3% | -174.0% | ||
| Q3 25 | 13.2% | -189.9% | ||
| Q2 25 | 8.4% | -232.8% | ||
| Q1 25 | -2.4% | 36.6% | ||
| Q4 24 | 18.5% | -154.2% | ||
| Q3 24 | 10.8% | -168.9% | ||
| Q2 24 | 26.2% | -206.2% | ||
| Q1 24 | 3.6% | -358.5% |
资本支出强度CIXRGNX
| Q4 25 | 1.6% | 1.7% | ||
| Q3 25 | 2.5% | 1.7% | ||
| Q2 25 | 3.3% | 1.8% | ||
| Q1 25 | 2.0% | 1.2% | ||
| Q4 24 | 0.6% | 5.1% | ||
| Q3 24 | 1.4% | 1.3% | ||
| Q2 24 | 1.2% | 2.1% | ||
| Q1 24 | 0.8% | 3.6% |
现金转化率CIXRGNX
| Q4 25 | 2.57× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 0.87× | — | ||
| Q1 25 | -0.03× | 5.53× | ||
| Q4 24 | 1.62× | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 2.03× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CIX
| Security Products | $29.5M | 78% |
| Marine Components | $8.2M | 22% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
